Brachytherapy: A new era

Radiotherapy and Oncology

Volumn 74, Issue 3, 2005, Pages 223-225

  Mazeron, Jean Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IRIDIUM 192;

BEAM THERAPY; BRACHYTHERAPY; BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSIMETRY; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECTUM CANCER; UTERINE CERVIX CANCER;

EID: 14844325825     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2005.02.001     Document Type: Article

References (26)

1. J.J. Mazeron, and A. Gerbaulet The centenary of discovery of radium Radiother Oncol 49 1998 205 216
2. Gerbaulet A, Pötter R, Mazeron JJ, Meertens H, Van Limbergen E. The GEC ESTRO hand book of brachytherapy. ESTRO Ed; 2002.
3. F. Guedea Patterns of care for brachytherapy in Europe (PCBE) (abstract) Radiother Oncol 71 2004 S1
4. J.J. Battermann, T.A. Boon, A. Marinus, and A. Moerland Results of permanent prostate brachytherapy, 13 years of experience of a single institution Radiother Oncol 71 2004 23 28
5. L. Potters, E.A. Klein, and M.W. Kattan Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation Radiother Oncol 71 2004 29 33
6. P.G. Koutrouvelis, J. Gillenwater, and N. Lailas High and intermediate risk prostate cancer treated with tri-dimensional computed tomography-guided brachytherapy: 2-8 year follow-up Radiother Oncol 67 2003 303 308
7. L. Aström, D. Pedersen, C. Mercke, S. Homäng, and K.A. Johansson Long term outcome of high dose rate brachytherapy of localized prostate cancer Radiother Oncol 74 2005 157 161
8. P. Nickers, E. Lenaerts, B. Thissen, and J.M. Deneufbourg Does inverse planning applied to Iridium-192 high dose rate prostate brachytherapy improve the optimisation of the dose afforded by the Paris system? Radiother Oncol 74 2005 131 136
9. T. Martin, S. Roddiger, and R. Kurek 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer Radiother Oncol 71 2004 35 41
10. P.J. Hoskin, P.J. Bownes, P. Ostler, K. Walker, and L. Bryant High dose rate brachytherapy for prostate cancer: catheter and gland movement between fractions Radiother Oncol 68 2003 285 288
11. G. Kovács, R. Pötter, and T. Loch GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for locolised prostate cancer Radiother Oncol 74 2004 137 148
12. D. Ash, A. Flynn, J. Battermann, Th. de Reike, P. Lavagnoni, and L. Blank ESTRO/EAU/EORTC recommendations on permanent implants for localised prostate cancer Radiother Oncol 57 2000 315 321
13. E.M. Horwitz, R.K. Mitra, and R.G. Uzzo Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) guidelines for trans ultrasound guided permanent Iodine 125 permanent implants Radiother Oncol 66 2003 173 179
14. B. Al-Qaisieh Pre- and post-implant dosimetry: an inter-comparison between UK prostate brachytherapy centers Radiother Oncol 66 2003 181 183
15. N. Wachter-Gertsner, S. Wachter, and E. Reinstadler Bladder and rectum dose defined from MRI based treatment planning for cervix cancer brachytherapy: comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point Radiother Oncol 68 2003 269 276
16. C. Haie-Meder, R. Pötter, and E. Van Limbergen Recommendations from Gynecological (GYN) GEC ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapu with emphasis on MRI management of GTV and CTV Radiother Oncol 74 2005 235 245
17. I.S. Fentiman, V. Deshmane, D. Tong, and J. Persliden Caesium 137 implant as sole therapy for operable breasr cancer: a phase II trial Radiother Oncol 71 2004 281 285
18. B. Johanson, E. Persson, G. Westman, J. Winter, H. Maqyles, and M.A. Chaudary Phantom study of radiation dose outside the target volume brachytherapy versus external radiotherapy of early breast cancer Radiother Oncol 69 2003 107 112
19. C.E.J. Hall, R. Harris, and R.A. A'Hern Le Fort I osteotomy and low-dose-rate Ir192 brachytherapy for treatment of recurrent nasophayngeal tumours Radiother Oncol 66 2003 41 48
20. N. Kakimoto, T. Inoue, and T. Inoue Results of low- and high-dose-rate interstial brachytherapy for T3 mobile tongue cancer Radiother Oncol 68 2003 123 128
21. C.E. Stannard, E. Hering, and J. Hough Post-operative treatment of malignant salivary gland tumours of the palate with Iodine-125 brachytherapy Radiother Oncol 73 2004 307 311
22. F. Ahmad, P. Aletti, and C. Chara-Braunaud Influence of dose point and inverse optomization on interstitial cervical and oropharyngeal carcinoma brachytherapy Radiother Oncol 73 2004 331 337
23. O. Coatmeur, G. Truc, I. Barillot, and P. Maingon Treatment of T1-T2 rectal tumours by contact therapy and interstitial brachytherapy Radiother Oncol 70 2004 177 182
24. I.K.K. Kolkman-Deurloo, J.J. Nuyttens, P.E.J. Hanssens, and P.C. Levendag Intraoperative HDR brachytherapy for rectal cancer using flexible intraoperative telmplate: standard plans versus individual planning Radiother Oncol 70 2004 75 79
25. P.J. Hoskin, S.M. de Cantha, P. Bownes, L. Bryant, and R.G. Jones High dose rate intraluminal brachytherapy for advanced inoperable rectal carcinoma Radiother Oncol 73 2004 195 198
26. S.A. Roberts, J.H. Hendry, R. Swindell, J.M. Wilkinson, and R.D. Hunter Compensations for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial Radiother Oncol 70 2004 63 74